- Home
- GRCE vs ONCY Comparison
GRCE vs ONCY Comparison
Compare GRCE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- ONCY
- Stock Information
- Founded
- GRCE 2002
- ONCY 1998
- Country
- GRCE United States
- ONCY Canada
- Employees
- GRCE N/A
- ONCY N/A
- Industry
- GRCE
- ONCY Pharmaceuticals and Biotechnology
- Sector
- GRCE
- ONCY Health Care
- Exchange
- GRCE NYSE
- ONCY Nasdaq
- Market Cap
- GRCE 42.1M
- ONCY 49.1M
- IPO Year
- GRCE N/A
- ONCY 1999
- Fundamental
- Price
- GRCE $2.94
- ONCY $0.77
- Analyst Decision
- GRCE Strong Buy
- ONCY Strong Buy
- Analyst Count
- GRCE 1
- ONCY 4
- Target Price
- GRCE $12.00
- ONCY $4.33
- AVG Volume (30 Days)
- GRCE 53.8K
- ONCY 1.2M
- Earning Date
- GRCE 06-23-2025
- ONCY 07-31-2025
- Dividend Yield
- GRCE N/A
- ONCY N/A
- EPS Growth
- GRCE N/A
- ONCY N/A
- EPS
- GRCE N/A
- ONCY N/A
- Revenue
- GRCE N/A
- ONCY N/A
- Revenue This Year
- GRCE N/A
- ONCY N/A
- Revenue Next Year
- GRCE N/A
- ONCY N/A
- P/E Ratio
- GRCE N/A
- ONCY N/A
- Revenue Growth
- GRCE N/A
- ONCY N/A
- 52 Week Low
- GRCE $1.75
- ONCY $0.33
- 52 Week High
- GRCE $4.97
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- ONCY 70.82
- Support Level
- GRCE N/A
- ONCY $0.56
- Resistance Level
- GRCE N/A
- ONCY $0.77
- Average True Range (ATR)
- GRCE 0.00
- ONCY 0.09
- MACD
- GRCE 0.00
- ONCY 0.02
- Stochastic Oscillator
- GRCE 0.00
- ONCY 88.51
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.